In this work, we present LesionLocator, a framework for zero-shot longitudinal lesion tracking and segmentation in 3D medical imaging, establishing the first end-to-end model capable of 4D tracking with dense spatial prompts. Our model leverages an extensive dataset of 23,262 annotated medical scans, as well as synthesized longitudinal data across diverse lesion types. The diversity and scale of our dataset significantly enhances model generalizability to real-world medical imaging challenges and addresses key limitations in longitudinal data availability. LesionLocator outperforms all existing promptable models in lesion segmentation by nearly 10 dice points, reaching human-level performance, and achieves state-of-the-art results in lesion tracking, with superior lesion retrieval and segmentation accuracy. LesionLocator not only sets a new benchmark in universal promptable lesion segmentation and automated longitudinal lesion tracking but also provides the first open-access solution of its kind, releasing our synthetic 4D dataset and model to the community, empowering future advancements in medical imaging. Code is available at: www.github.com/MIC-DKFZ/LesionLocator

OBJECTIVES: Breast diffusion-weighted imaging (DWI) has shown potential as a standalone imaging technique for certain indications, eg, supplemental screening of women with dense breasts. This study evaluates an artificial intelligence (AI)-powered computer-aided diagnosis (CAD) system for clinical interpretation and workload reduction in breast DWI. MATERIALS AND METHODS: This retrospective IRB-approved study included: n = 824 examinations for model development (2017-2020) and n = 235 for evaluation (01/2021-06/2021). Readings were performed by three readers using either the AI-CAD or manual readings. BI-RADS-like (Breast Imaging Reporting and Data System) classification was based on DWI. Histopathology served as ground truth. The model was nnDetection-based, trained using 5-fold cross-validation and ensembling. Statistical significance was determined using McNemar's test. Inter-rater agreement was calculated using Cohen's kappa. Model performance was calculated using the area under the receiver operating curve (AUC). RESULTS: The AI-augmented approach significantly reduced BI-RADS-like 3 calls in breast DWI by 29% (P =.019) and increased interrater agreement (0.57 ± 0.10 vs 0.49 ± 0.11), while preserving diagnostic accuracy. Two of the three readers detected more malignant lesions (63/69 vs 59/69 and 64/69 vs 62/69) with the AI-CAD. The AI model achieved an AUC of 0.78 (95% CI: [0.72, 0.85]; P <.001), which increased for women at screening age to 0.82 (95% CI: [0.73, 0.90]; P <.001), indicating a potential for workload reduction of 20.9% at 96% sensitivity. DISCUSSION AND CONCLUSION: Breast DWI might benefit from AI support. In our study, AI showed potential for reduction of BI-RADS-like 3 calls and increase of inter-rater agreement. However, given the limited study size, further research is needed.